These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20216273)

  • 41. Relevance of the results of the Women's Health Initiative on the prescription of hormone therapy in Spain.
    Neyro JL; Cancelo MJ; Quereda F; Palacios S;
    Climacteric; 2005 Mar; 8(1):36-48. PubMed ID: 15804730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing?
    Mikkola TS; Clarkson TB
    J Womens Health (Larchmt); 2006; 15(1):51-3. PubMed ID: 16417418
    [No Abstract]   [Full Text] [Related]  

  • 43. The Women's Health Initiative - a decade of progress.
    Fenton A; Panay N
    Climacteric; 2012 Jun; 15(3):205. PubMed ID: 22612604
    [No Abstract]   [Full Text] [Related]  

  • 44. Menopause: a new era.
    Peters S
    Adv Nurse Pract; 1998 Jul; 6(7):61-4. PubMed ID: 9782801
    [No Abstract]   [Full Text] [Related]  

  • 45. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income.
    Wei F; Miglioretti DL; Connelly MT; Andrade SE; Newton KM; Hartsfield CL; Chan KA; Buist DS
    J Natl Cancer Inst Monogr; 2005; (35):106-12. PubMed ID: 16287895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Women's Health Initiative: not over yet. The largest study of women's health has raised at least as many questions as it has answered. Stay tuned.
    Harv Womens Health Watch; 2006 May; 13(9):1-4. PubMed ID: 16696133
    [No Abstract]   [Full Text] [Related]  

  • 47. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK; Governale LA
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Estrogen and cardiovascular diseases].
    Mikkola T; Tikkanen MJ
    Duodecim; 2003; 119(22):2191-7. PubMed ID: 14702808
    [No Abstract]   [Full Text] [Related]  

  • 50. [Hormone replacement therapy: the pros].
    Jamin C; Madelenat P
    Gynecol Obstet Fertil; 2008 Jan; 36(1):98-103. PubMed ID: 18248839
    [No Abstract]   [Full Text] [Related]  

  • 51. [Should hormone replacement therapy for menopause be continued in diabetic women?].
    Skurnik G; Touraine P
    Journ Annu Diabetol Hotel Dieu; 2004; ():151-60. PubMed ID: 15259313
    [No Abstract]   [Full Text] [Related]  

  • 52. The Women's Health Initiative: an unforgettable decade.
    Pal L; Manson JE
    Menopause; 2012 Jun; 19(6):597-9. PubMed ID: 22648299
    [No Abstract]   [Full Text] [Related]  

  • 53. A natural way to age.
    Kalb C
    Newsweek; 2002 Dec; 140(23):64-5. PubMed ID: 12501515
    [No Abstract]   [Full Text] [Related]  

  • 54. Promoting health for older women.
    Black F
    Nurs Manag (Harrow); 1999 Feb; 5(9):30-1. PubMed ID: 10205497
    [No Abstract]   [Full Text] [Related]  

  • 55. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research.
    Henderson VW
    Neuroscience; 2006; 138(3):1031-9. PubMed ID: 16310963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pitfalls of the WHIs: Women's Health Initiative.
    Mastorakos G; Sakkas EG; Xydakis AM; Creatsas G
    Ann N Y Acad Sci; 2006 Dec; 1092():331-40. PubMed ID: 17308158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacology and differential cognitive efficacy of estrogen preparations.
    Gleason CE; Carlsson CM; Johnson S; Atwood C; Asthana S
    Ann N Y Acad Sci; 2005 Jun; 1052():93-115. PubMed ID: 16024754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.